<DOC>
	<DOCNO>NCT02428478</DOCNO>
	<brief_summary>Obstructive sleep apnea ( OSA ) common major health implication treatment option limit . OSA patient show marked reduction upper airway ( UA ) dilator muscle activity sleep onset phenomenon lead increase collapsibility UA compare normal participant . Until recently , search medicine activate pharyngeal muscle sleep human discourage . However , excite new animal research show drug noradrenergic antimuscarinic effect restore pharyngeal muscle activity waking level . In protocol investigator test effect desipramine ( tricyclic antidepressant strong noradrenergic antimuscarinic effect ) genioglossus muscle activity ( EMG GG ) sleep healthy control participant .</brief_summary>
	<brief_title>Effect Desipramine Genioglossus Muscle Activity Healthy Adults Study A</brief_title>
	<detailed_description>Two overnight sleep study , placebo night drug night , perform approximately one week apart random order . The placebo drug administer 2 hour light . At least 15 minute quiet wakefulness record quantify participant 's awake EMG GG activity . Participants sleep lateral position minimize pharyngeal resistance similar previous study kind . The do stable non-rapid eye movement ( NREM ) rapid eye movement ( REM ) sleep ( free arousal artifact ) . Both NREM REM sleep analyze , recognize REM le frequent drug . During second part night , participant connect modified continuous positive airway pressure ( CPAP ) machine ( Pcrit3000 , Respironics ) provide wide range pressure 20 -20 cm H2O order modify upper airway pressure measure change EMG GG function epiglottic pressure ( muscle responsiveness ) .</detailed_description>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<criteria>Healthy control subject Cardiovascular disease well control hypertension Depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>